Quipt Home Medical Corp.

Overview

• IndustryServices-Misc Health & Allied Services, NEC¹
• HeadquartersWilder, Kentucky¹
• Incorporated inBritish Columbia, Canada²
• Business address1019 Town Drive, Wilder, Ky 41076²
• Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Quipt Home Medical Corp. and its subsidiaries (“Quipt” or the “Company”), is a provider of durable medical equipment (“DME”) / home medical equipment (“HME”) in the United States (“US”). The Company specializes in delivering effective in-home treatments for managing various chronic conditions, with a primary focus on respiratory diseases. The Company’s comprehensive solutions support patients dealing with heart and pulmonary diseases, sleep apnea, reduced mobility, and other chronic health challenges. Currently, the Company serves patients across 27 states in the US.⁴ From its latest annual report

Corporate structure

Quipt Home Medical Corp. sits at the top of its group. 61 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Quipt Home Medical Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

The Company’s total space is approximately 750,000 square feet, and consists of warehouse, retail, and administrative offices. The Company leases all but one of its over 175 facilities. The following is a summary of the Company’s largest facilities by location:

Square

Item 2 of the 10-K filed Dec 15, 2025.⁴

Leadership

Who has led Quipt Home Medical Corp., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerGregory John Crawford Oct 1, 2024 to now¹⁴
• PresidentGregory John Crawford Oct 1, 2024 to now¹⁴
• Chief financial officerHardik Mehta Oct 1, 2024 to now¹⁵

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• 100 W. Commercial Street, LLC Missouri³
• Acadia Medical Supply, Inc. Maine³
• Access Respiratory Home Care, L.L.C. Louisiana³
• Advanced Medical DME, LLC Kansas³
• Alliance Homecare & Mobile Diagnostics, L.L.C. Arizona³
• At Home Health Equipment, LLC Indiana³
• Black Bear Medical Group, Inc. Maine³
• Black Bear Medical NH, Inc. New Hampshire³
• Black Bear Medical, Inc. Maine³
• Care Medical Atlanta, LLC Georgia³
• Care Medical Partners LLC Georgia³
• Care Medical Savannah, LLC Georgia³
• Care Medical of Athens, Inc. Georgia³
• Care Medical of Augusta, LLC Georgia³
• Care Medical of Gainesville, LLC Georgia³
• Central Oxygen, Inc. Indiana³
• Coastal Med-Tech Corp. Maine³
• Cooley Medical Equipment, Incorporated Kentucky³
• Focus Respiratory, LLC Arizona³
• Good Night Medical of Ohio, LLC Ohio³
• Good Night Medical of Texas, Inc Texas³
• Good Night Medical, LLC Ohio³
• Great Elm Healthcare, LLC Delaware³
• Health Technology Resources, LLC Illinois³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• Protech Home Medical Corp.Jul 31, 2020 to May 14, 2021²
• Patient Home Monitoring Corp.Jan 19, 2012 to Oct 3, 2017²

Timeline

1. Mar 16, 20268-K Entered a material agreement; Completed an acquisition or sale; Listing notice or transfer²³
2. Mar 6, 20268-K Other events²⁴
3. Mar 3, 20268-K Shareholder vote; Other events²⁵
4. Jan 26, 20268-K Other events²⁶
5. Jan 6, 20268-K Other events²⁷
6. Dec 15, 20258-K Entered a material agreement; Regulation FD disclosure²⁸
7. Dec 15, 20258-K Results of operations²⁹
8. Aug 27, 20258-K Regulation FD disclosure³⁰
9. Aug 12, 20258-K Entered a material agreement; Other events³¹
10. Aug 11, 20258-K Results of operations³²
11. Jul 7, 20258-K Other events³³
12. May 21, 20258-K Regulation FD disclosure³⁴
13. Oct 1, 2024New chief executive Gregory John Crawford becomes CEO¹⁴

Calendar

When it reported results

1. Dec 15, 2025Reported quarterly or annual results²⁹
2. Aug 11, 2025Reported quarterly or annual results³²
3. May 12, 2025Reported quarterly or annual results³⁵
4. Feb 10, 2025Reported quarterly or annual results³⁶
5. Dec 16, 2024Reported quarterly or annual results³⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

193 filings to the SEC since October 2021: 7 annual reports, 4 quarterly reports, 19 major events, 35 insider forms, 23 large holders, 105 other. The latest 20:

1. May 14, 2026SCHEDULE 13G/A EDGAR
2. Mar 26, 202615-12G EDGAR
3. Mar 16, 2026SCHEDULE 13D/A EDGAR
4. Mar 16, 20264 OWNERSHIP DOCUMENT EDGAR
5. Mar 16, 20264 OWNERSHIP DOCUMENT EDGAR
6. Mar 16, 20264 OWNERSHIP DOCUMENT EDGAR
7. Mar 16, 20264 OWNERSHIP DOCUMENT EDGAR
8. Mar 16, 20264 OWNERSHIP DOCUMENT EDGAR
9. Mar 16, 20264 OWNERSHIP DOCUMENT EDGAR
10. Mar 16, 20264 OWNERSHIP DOCUMENT EDGAR
11. Mar 16, 20264 OWNERSHIP DOCUMENT EDGAR
12. Mar 16, 20264 OWNERSHIP DOCUMENT EDGAR
13. Mar 16, 2026S-8 POS EDGAR
14. Mar 16, 2026S-8 POS EDGAR
15. Mar 16, 2026F-10POS EDGAR
16. Mar 16, 20268-K EDGAR
17. Mar 6, 20268-K EDGAR
18. Mar 3, 20268-K EDGAR
19. Feb 10, 2026SCHEDULE 13G/A EDGAR
20. Feb 9, 202610-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• GLAZER CAPITAL, LLCSCHEDULE 13G/A, 2 filings Jan 15, 2026 to May 14, 2026³⁸
• Forager Fund, L.P.SCHEDULE 13D/A, 9 filings Dec 11, 2024 to Mar 16, 2026³⁹
• Claret Asset Management CorpSCHEDULE 13G/A, 5 filings Jan 20, 2022 to Feb 10, 2026⁴⁰
• Lakeview Opportunity Fund LLCSCHEDULE 13D, 1 filing Nov 7, 2025⁴¹
• Philotimo Fund, LPSCHEDULE 13D/A, 4 filings Jan 10, 2025 to May 28, 2025⁴²
• BlackRockSC 13G/A, 2 filings Feb 2, 2024 to Feb 7, 2024⁴³

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How Quipt Home Medical Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARQuipt Home Medical Corp.¹
• CIK0001540013
• Employer ID (EIN)00-0000000⁴
• Filer statusAccelerated filer an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inBritish Columbia, Canada⁴
• Fiscal year endsSeptember 30¹
• Industry code (SIC)8090 Services-Misc Health & Allied Services, NEC¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address1019 Town Drive, Wilder, KY 41076¹
• Phone859-878-2220¹
• Shares outstanding44,464,972 as of Feb 6, 2026¹²
• Public float$90.9M as of Mar 31, 2025⁴
• AuditorBDO USA, P.C., Cincinnati, Ohio PCAOB ID 243; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceJan 19, 2012¹
• Filings237 in all: 6-K (85), 4 (26), D (25), 8-K (19), DEFA14A (10), 3 (9), SCHEDULE 13D/A (9), 10-Q (4)¹
  All 38 form types

  SC 13G/A (4), 40-F (3), F-10/A (3), F-X (3), S-8 (3), S-8 POS (3), SC 13G (3), SCHEDULE 13G/A (3), 10-K (2), F-10 (2), SCHEDULE 13D (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 40-F/A (1), 40FR12B (1), 40FR12B/A (1), 6-K/A (1), ARS (1), CERT (1), DEF 14A (1), DEFM14A (1), EFFECT (1), F-10POS (1), PREM14A (1), RW (1), SC 13D (1), SCHEDULE 13G (1), SEC STAFF ACTION (1), SUPPL (1)

• Latest filingsAnnual report (10-K) Dec 15, 2025
  Quarterly report (10-Q) Feb 9, 2026
  Proxy statement (DEF 14A) Jan 24, 2025
  Latest 8-K (8-K) Mar 16, 2026

Securities registered for trading

From the cover page of the 10-K filed Dec 15, 2025 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Quipt Home Medical Corp. names in Item 1A of its 10-K filed Dec 15, 2025: 48 risks under these headings, as written.⁴

• We operate in a rapidly changing environment that involves a number of risks. The following discussion highlights some of these risks and others are discussed elsewhere in this report. These and other risks could materially adversely affect our business, revenue, financial condition and results of operations. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. See also “Cautionary Note Regarding Forward-Looking Statements” in this Annual Report on Form 10-K.
• Risks Related to Our Business and Industry
• Reliance on relatively few suppliers for the majority of Quipt’s patient service equipment and supplies could adversely affect Quipt’s ability to operate.
• Supply chain disruptions and economy-wide labor shortages in the U.S. could negatively impact Quipt’s businesses.
• Quipt has been negatively impacted by inflation and rising interest rates.
• Quipt’s business depends on its information systems, including software licensed from or hosted by third parties, and any failure or significant disruption or effective cyber-attack on any of these systems, security breaches or improper disclosure of or loss of data could materially affect our business, results of operations and financial condition.
• Quipt’s financial performance is affected by continuing efforts by private third-party payors to control their costs, and if Quipt agrees to lower its reimbursement rates due to pricing pressures from such private third-party payors, Quipt’s financial condition and results of operations would likely deteriorate.
• Quipt’s payor contracts are subject to renegotiation or termination, which could result in a decrease in Quipt’s revenue or profits.
• Changes made by payors to the way they cover products supplied by Quipt could have an adverse impact on Quipt’s revenue and operations.
• Changes in governmental or private payor supply replenishment schedules could adversely affect Quipt.
• If Quipt fails to manage the complex and lengthy reimbursement process, its revenue, financial condition and results of operations could suffer.
• Quipt may be adversely affected by consolidation among health insurers and other industry participants.

Legal proceedings

From time to time, the Company is involved in various legal proceedings and investigations arising in the ordinary course of business, including those relating to proxy contests and other actions of activist shareholders, employment matters, relationships with clients and contractors, intellectual property disputes and other business matters. The outcomes of our legal proceedings and other contingencies are inherently unpredictable, subject to significant uncertainties, and if one or more legal matters were resolved against the Company in a reporting period for amounts above management’s expectations, the Company’s financial condition and operating results for that period could be materially adversely affected.

The Company has received a civil investigative demand (“CID”) from the Department of Justice (“DOJ”) through the US Attorney’s Office for the Northern District of Georgia pursuant to the False Claims Act regarding an investigation concerning whether the Company may have caused the submission of false claims to government healthcare programs for CPAP equipment. The Company is cooperating with the investigation. No assurance can be given as to the timing or outcome of the DOJ’s investigation.

In April 2024, the Company received a subpoena from the SEC to provide certain documents related to the Company and the DOJ investigation, CID, and financial reporting and disclosure matters. The SEC concluded its investigation in November 2024 and, based on the information it had at such time, the SEC advised that it did not intend to recommend an enforcement action by it against the Company.

The opening of Item 3, Legal Proceedings.⁴